Quick Answer
AXIM BIOTECHNOLOGIES, INC. reported Gross Profit of $187.1 thousand for the year ending 2018.
- AXIM BIOTECHNOLOGIES, INC. showed an increase of +3,867.4% in Gross Profit from 2017 to 2018.
- This data is from AXIM BIOTECHNOLOGIES, INC.'s annual report (Form 10-K), filed with the SEC on April 8, 2019.
- XBRL data for this metric is available from 2016 to 2018 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2014: $0.00 | Q3 2015: -$11.2 thousand | Q1 2016: -$1.2 thousand | Q2 2016: -$841.00 | Q3 2016: -$4.1 thousand | Q1 2017: -$20.3 thousand | Q2 2017: $2.3 thousand | Q3 2017: $8.1 thousand | Q1 2018: $12.5 thousand | Q2 2018: $5.9 thousand | Q3 2018: $3.0 thousand | Q1 2019: $12.7 thousand | Q2 2019: $5.4 thousand | Q3 2019: $76.7 thousand | Q2 2021: $14.9 thousand | Q2 2023: $9.9 thousand | Q2 2024: $15.7 thousand.
- Over the full 3 years of available data (2016 to 2018), AXIM BIOTECHNOLOGIES, INC.'s Gross Profit has grown by 274.7%.
- Historical annual values: Fiscal year 2018: $187.1 thousand | Fiscal year 2017: $4.7 thousand | Fiscal year 2016: -$107.1 thousand.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: